Article Text

PDF
General practitioners and postmarketing surveillance

Abstract

Many new drugs or new formulations will have been given to less than two thousand patients at the time a licence is issued. Clinical studies carried out before marketing will have demonstrated the drug’s main effects and its apparent safety. Adverse effects may only be recognised much later when a large number of patients have been treated. This was the case with benoxaprofen, Osmosin, zimeldine and zomepirac. The speedy recognition of such problems requires the help of all prescribers, but particularly of GPs who are especially likely to prescribe newly promoted drugs. Government has promised funds to help improve the collection and dissemination of information about drug safety.1

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.